Patents Assigned to PHARMACYCLICS LLC
-
Patent number: 11672803Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.Type: GrantFiled: July 10, 2020Date of Patent: June 13, 2023Assignee: Pharmacyclics LLCInventor: Joseph J. Buggy
-
Patent number: 10961251Abstract: Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.Type: GrantFiled: November 18, 2020Date of Patent: March 30, 2021Assignee: Pharmacyclics LLCInventors: Norbert Purro, Mark S. Smyth, Erick Goldman, David D. Wirth
-
Patent number: 10954567Abstract: Described herein are mutations that confer resistance to treatment with a BTK inhibitor. Described herein are modified BTK polypeptides that exhibit decreased inhibition (i.e. are resistant) to a covalent and/or irreversible BTK inhibitor. Also described herein modifications of PLCy2 and CARD 11 polypeptides that confer resistance to treatment with a BTK inhibitor. Described herein are diagnostic methods for detecting the modified polypeptides and nucleic acids encoding the modified polypeptides and applications of the methods thereof. Described herein are compositions, combinations, and kits containing the modified polypeptides and methods of using the modified polypeptides. Also described herein are methods of using modified BTK polypeptides as screening agents for the identification and design of second-generation BTK inhibitors.Type: GrantFiled: July 23, 2013Date of Patent: March 23, 2021Assignees: Pharmacyclics LLC, Cornell UniversityInventors: Betty Chang, Joseph J. Buggy, Susanne M. Steggerda
-
Patent number: 10898461Abstract: Described herein are salts of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide, in particular that of formula (I): wherein HA is naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, oxalic acid, benzenesulfonic acid, or sulfuric acid, or hydrates thereof, and crystalline forms thereof characterized by the powder X-ray diffraction diagram and the 13C CP/MAS NMR solid state spectrum. Also described are compositions, methods of use and preparation thereof.Type: GrantFiled: November 7, 2019Date of Patent: January 26, 2021Assignee: Pharmacyclics LLCInventors: Marina Gaillard, Philippe Letellier
-
Patent number: 10828259Abstract: Described herein are pharmaceutical formulations of Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one. Also disclosed are methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.Type: GrantFiled: April 10, 2020Date of Patent: November 10, 2020Assignee: Pharmacyclics LLCInventors: Ching W. Chong, Robert Kuehl, Heow Tan, Harisha Atluri
-
Patent number: 10751342Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.Type: GrantFiled: January 21, 2020Date of Patent: August 25, 2020Assignee: Pharmacyclics LLCInventors: Joseph J. Buggy, Gwen Fyfe, Lee Honigberg, David J. Loury
-
Patent number: 10752634Abstract: Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.Type: GrantFiled: April 1, 2020Date of Patent: August 25, 2020Assignee: Pharmacyclics LLCInventors: Norbert Purro, Mark S. Smyth, Erick Goldman, David D. Wirth
-
Patent number: 10695350Abstract: Described herein are methods for treating and preventing graft versus host disease using ACK inhibitors. The methods include administering to an individual in need thereof an ACK inhibitor such as ibrutinib for treating and preventing graft versus host disease.Type: GrantFiled: September 25, 2019Date of Patent: June 30, 2020Assignee: Pharmacyclics LLCInventors: John C. Byrd, Jason A. Dubovsky, Natarajan Muthusamy, Amy J. Johnson, David Miklos
-
Patent number: 10653696Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.Type: GrantFiled: August 8, 2019Date of Patent: May 19, 2020Assignee: Pharmacyclics LLCInventors: Joseph J. Buggy, Gwen Fyfe, Lee Honigberg, David J. Loury
-
Patent number: 10478439Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.Type: GrantFiled: April 27, 2018Date of Patent: November 19, 2019Assignee: Pharmacyclics LLCInventors: Lee Honigberg, David J. Loury
-
Patent number: 10463668Abstract: Described herein are methods for treating and preventing graft versus host disease using ACK inhibitors. The methods include administering to an individual in need thereof an ACK inhibitor such as ibrutinib for treating and preventing graft versus host disease.Type: GrantFiled: May 3, 2017Date of Patent: November 5, 2019Assignee: Pharmacyclics LLCInventors: John C. Byrd, Jason A. Dubovsky, Natarajan Muthusamy, Amy J. Johnson, David Miklos
-
Patent number: 10294231Abstract: Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.Type: GrantFiled: August 23, 2018Date of Patent: May 21, 2019Assignee: Pharmacyclics LLCInventors: Norbert Purro, Mark S. Smyth, Erick Goldman, David D. Wirth
-
Patent number: 10294232Abstract: Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.Type: GrantFiled: August 23, 2018Date of Patent: May 21, 2019Assignee: Pharmacyclics LLCInventors: Norbert Purro, Mark S. Smyth, Erick Goldman, David D. Wirth
-
Patent number: 10266540Abstract: Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.Type: GrantFiled: July 13, 2018Date of Patent: April 23, 2019Assignee: Pharmacyclics LLCInventors: Norbert Purro, Mark S. Smyth, Erick Goldman, David D. Wirth
-
Publication number: 20190112312Abstract: Disclosed herein are amido compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.Type: ApplicationFiled: May 18, 2018Publication date: April 18, 2019Applicant: Pharmacyclics LLCInventors: Wei Chen, Longcheng Wang, Zhaozhong J. Jia
-
Publication number: 20190100505Abstract: Disclosed herein are reversible and irreversible inhibitors of Bruton's tyrosine kinase (Btk). Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are described, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.Type: ApplicationFiled: May 15, 2018Publication date: April 4, 2019Applicant: Pharmacyclics LLCInventors: Wei Chen, Zhaozhong J. Jia, William D. Thomas
-
Patent number: 10226466Abstract: Disclosed are methods of treating fibrosis in a patient, comprising administering to a patient in need thereof a therapeutically effective amount of an ACK inhibitor (e.g., a BTK inhibitor, such as for example an irreversible BTK inhibitor, such as for example, ibrutinib).Type: GrantFiled: December 8, 2017Date of Patent: March 12, 2019Assignee: Pharmacyclics LLCInventors: Toni Jauset González, Daniel Massó-Vallés, Laura Soucek
-
Patent number: 10213386Abstract: Described herein are pharmaceutical formulations of Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one. Also disclosed are methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.Type: GrantFiled: May 3, 2018Date of Patent: February 26, 2019Assignee: Pharmacyclics LLCInventors: Ching W. Chong, Robert Kuehl, Heow Tan, Harisha Atluri
-
Patent number: 10150748Abstract: Abexinostat tosylate of formula (II): and its crystalline form I characterized by its X-ray powder diffraction diagram, its Raman spectrum and its solid-state 13C CP/MAS NMR spectrum. Medicinal products containing the same which are useful in the treatment of cancer.Type: GrantFiled: January 12, 2017Date of Patent: December 11, 2018Assignee: Pharmacyclics, LLCInventors: Anne Pimont-Garro, Philippe Letellier
-
Patent number: 10125140Abstract: Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.Type: GrantFiled: July 16, 2018Date of Patent: November 13, 2018Assignee: Pharmacyclics LLCInventors: Norbert Purro, Mark S. Smyth, Erick Goldman, David D. Wirth